Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis.
Yao ZhangHuiting LiBo YuSi SunZhihuang HuXianghua WuYang ZhangBin LiYawei ZhangJiaqing XiangJialei WangHui YuPublished in: Thoracic cancer (2024)
NCIT is safe and provides potential survival benefits for patients with locally advanced ESCC. However, randomized phase 3 trial data is still needed.
Keyphrases
- locally advanced
- rectal cancer
- electronic health record
- squamous cell carcinoma
- neoadjuvant chemotherapy
- big data
- double blind
- radiation therapy
- case report
- open label
- placebo controlled
- phase iii
- clinical trial
- randomized controlled trial
- data analysis
- machine learning
- artificial intelligence
- free survival
- phase ii
- risk assessment
- deep learning